“An Update on Cannabidiol (CBD) Use in Pediatric Treatment-Resistant Epilepsy” By Dr. Brenda Porter
July 19, 2018 12:00 PM PDT
Severe childhood epilepsies are characterized by a high seizure burden and are often associated with neurodevelopmental delays. When traditional medications fail to control a child’s seizures, families look to alternative treatments to help their children. One of the alternative treatments such as the use of a compound from the Cannabis plant, Cannabidiol (CBD) have become more widespread over the past year. CBD is a non-psychoactive compound that has been shown to have anticonvulsive properties in a number of animal models of epilepsy. There is exciting data about the use of CBD in children with intractable epilepsy and recently an advisory panel at the FDA unanimously voted to recommend approval for CBD to treat seizures in certain forms of childhood epilepsy. The data on CBD for epilepsy are promising, and CBD is being considered as a treatment of other neurologic conditions.
Webinar Presenter: Brenda E. Porter, MD, Ph.D. is a professor of neurology at Stanford University.
Dr. Porter is a pediatric neurologist with a special interest in pediatric epilepsy. She is director of the pediatric epilepsy division at Lucile Packard Children’s Hospital and co-director of the Tuberous Sclerosis clinic at Stanford.